| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
(E)-Methyl caffeate interacts with multiple molecular targets. In breast cancer MCF-7 cells, it modulates apoptosis-related proteins by downregulating Bcl-2 while upregulating Bid and Bax . It also inhibits α-glucosidase, contributing to its antidiabetic effects, and upregulates GLUT4 expression in pancreatic tissue . In vascular endothelial cells, it downregulates the VEGF/VEGFR‑2 signaling axis and its downstream cascades, including AKT-mTOR and MEK1/2-ERK1/2 . Additionally, it has been shown to inhibit HIV-1 replication in vitro .
|
|---|---|
| ln Vitro |
(E)-Methyl caffeate demonstrates potent anticancer activity. Against MCF-7 breast cancer cells, the compound exhibits an IC₅₀ of 0.62 μM after 24 hours of treatment . It significantly reduces cell proliferation and increases the formation of fragmented DNA and apoptotic bodies . The compound demonstrates stronger cytotoxic properties against MCF-7 cells compared to A549 (lung), COLO320 (colon), and HepG-2 (liver) cancer cells . It also exhibits antibacterial efficacy against Pseudomonas, Klebsiella, and Mycobacterium species, and inhibits HIV-1 replication in various in vitro models .
|
| ln Vivo |
In diabetic rat models, (E)-Methyl caffeate administration decreases blood glucose levels and upregulates GLUT4 expression, while also promoting the regeneration of β-cells in the pancreas . It has also demonstrated activity in the inhibition of HIV‑1 replication in vivo .
|
| Enzyme Assay |
An accurate Enzyme Assay protocol was not detailed in the selected references. However, the compound's has been shown to inhibit α-glucosidase activity, an enzyme involved in carbohydrate digestion, which contributes to its antidiabetic mechanism . The inhibition of HIV-1 replication was assessed in vitro using infected cell models, where the compound prevented viral propagation .
|
| Cell Assay |
The anticancer activity of (E)-Methyl caffeate was evaluated using human cancer cell lines including MCF-7 (breast), A549 (lung), COLO320 (colon), and HepG-2 (liver), as well as Vero cells . Cells were cultured in appropriate media and treated with varying concentrations of the compound. Cell proliferation was measured, and apoptosis was assessed by detecting fragmented DNA and apoptotic body formation. Bcl-2, Bid, and Bax protein expression levels were analyzed to elucidate the mechanism of caspase-dependent apoptosis via cytochrome c release from the mitochondria .
|
| Animal Protocol |
In a diabetic rat model, (E)-Methyl caffeate was administered orally to evaluate its hypoglycemic effects and pancreatic β-cell regeneration potential . A general in vivo formulation protocol suggests dissolving the compound in a vehicle of 5% DMSO, 30% PEG300, 5% Tween 80, and 60% saline or PBS for injection, based on the desired dosage and animal weight . Stock solutions are typically prepared by dissolving the compound in DMSO first, followed by sequential addition of co-solvents .
|
| ADME/Pharmacokinetics |
(E)-Methyl caffeate is predicted to have favorable ADME properties suitable for drug discovery. The compound does not violate Lipinski's rule of five, indicating good oral bioavailability potential . Its logP value is calculated to be 2.064 .
|
| Toxicity/Toxicokinetics |
(E)-Methyl caffeate (CAS 67667-67-8) is classified as causing skin irritation (H315) . General safety precautions include avoiding skin contact and using personal protective equipment. In a computational toxicology assessment, methyl caffeate was categorized into toxic hazard class I, indicating a low toxic hazard profile, alongside other caffeic acid derivatives . The product is strictly for research use only and not for human therapeutic applications .
|
| References |
[1]. https://pubchem.ncbi.nlm.nih.gov/compound/689075
|
| Additional Infomation |
Methyl caffeate is an alkyl caffeic acid ester formed by the condensation of caffeic acid and methanol. It is both an alkyl caffeic acid ester and a methyl ester. Methyl caffeate has been reported to exist in black cohosh (Meum athamanticum), Hypericum ascyron, and other organisms with relevant data.
(E)-Methyl caffeate (CAS 67667-67-8) has a purity of ≥98% and appears as an off-white to brown solid powder . Its melting point is approximately 160-163°C . The compound is soluble in organic solvents such as DMSO (up to 250 mg/mL), acetone, methanol, and ethyl acetate . For storage, the powder should be kept at -20°C for up to 3 years, while solutions should be stored at -80°C for up to 6 months . A related oxidative-coupling derivative, K20E, has been shown to exhibit anti-angiogenic activities through the down-regulation of VEGF and VEGFR-2 . |
| Molecular Formula |
C10H10O4
|
|---|---|
| Molecular Weight |
194.18
|
| Exact Mass |
222.089
|
| CAS # |
67667-67-8
|
| PubChem CID |
689075
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
160 °C
|
| LogP |
2.064
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
224
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1=C(C([H])=C([H])C(/C(/[H])=C(\[H])/C(=O)OC([H])([H])[H])=C1[H])O[H]
|
| InChi Key |
OCNYGKNIVPVPPX-HWKANZROSA-N
|
| InChi Code |
InChI=1S/C10H10O4/c1-14-10(13)5-3-7-2-4-8(11)9(12)6-7/h2-6,11-12H,1H3/b5-3+
|
| Chemical Name |
methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| Synonyms |
Methyl caffeate; 3843-74-1; Caffeic acid methyl ester; METHYLCAFFEATE; ...; 67667-67-8;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL | |
| 5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL | |
| 10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
